REGENXBIO (RGNX) – Research Analysts’ Recent Ratings Changes

Posted by Stanley Muller on Aug 31st, 2026

A number of research firms have changed their ratings and price targets for REGENXBIO (NASDAQ: RGNX):

8/25/2026 – REGENXBIO had its price target lowered by HC Wainwright from $23.00 to $21.00. They now have a “buy” rating on the stock.
8/25/2026 – REGENXBIO had its price target lowered by Robert W. Baird from $32.00 to $29.00. They now have an “outperform” rating on the stock.
8/12/2026 – REGENXBIO was upgraded by Zacks Research from “strong sell” to “hold”.
8/10/2026 – REGENXBIO had its price target lowered by HC Wainwright from $26.00 to $23.00. They now have a “buy” rating on the stock.
8/8/2026 – REGENXBIO was upgraded by Wall Street Zen from “strong sell” to “hold”.
8/7/2026 – REGENXBIO had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $18.00 price target on the stock.
8/7/2026 – REGENXBIO was downgraded by Barclays PLC from “overweight” to “hold”.
8/7/2026 – REGENXBIO had its “equal weight” rating reaffirmed by Barclays PLC. They now have a $12.00 price target on the stock.
7/14/2026 – REGENXBIO was downgraded by Zacks Research from “hold” to “strong sell”.

Insider Activity

In other news, insider Steve Pakola sold 36,725 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $12.86, for a total transaction of $472,283.50. Following the completion of the sale, the insider owned 213,009 shares of the company’s stock, valued at $2,739,295.74. This trade represents a 14.71% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. In the last quarter, insiders sold 58,494 shares of company stock worth $718,232. 14.22% of the stock is currently owned by corporate insiders.

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.

REGENXBIO (RGNX) – Research Analysts’ Recent Ratings Changes

Insider Activity

See Also

You might be interested in: